SCLX vs SLDB

Scilex Holding Company vs Solid Biosciences Inc. — Valuation Comparison 2026

SCLX

Biological Products, (No Diagnostic Substances)
Scilex Holding Company
Quality
4.7
out of 10
Value Trap
44
WARN
Price
$8.90
Last close
Models
5/13
Active
VS

SLDB

Biological Products, (No Diagnostic Substances)
Solid Biosciences Inc.
Quality
4.4
out of 10
Value Trap
18
SAFE
Price
$7.34
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType SCLX Fair ValueSCLX Upside SLDB Fair ValueSLDB Upside
Bayesian DCF Intrinsic $33.36 +463.5% $3.30 -55.1%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $4.75 -35.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $13.55 +52.2%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SCLX vs SLDB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SCLX vs SLDB — Which Stock Is More Undervalued?

SCLX scores higher with a 4.7/10 quality rating vs SLDB's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Scilex Holding Company (SCLX) and Solid Biosciences Inc. (SLDB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SCLX currently trades at $8.90 with a QOC of 4.7/10, while SLDB trades at $7.34 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).